$5,000.00
The American Heart Association (AHA) Scientific Sessions 2016 was held in New Orleans, LA from November 12-16. The most interesting results were from PCSK9 inhibitors, with details from Repatha’s positive atherosclerosis imaging study and Phase II data.
The American Heart Association (AHA) Scientific Sessions 2016 was held in New Orleans, LA from November 12-16. The most interesting results were from PCSK9 inhibitors, with details from Repatha’s positive atherosclerosis imaging study and Phase II data from inclisiran confirming the possibility of very prolonged dosing. Other studies on IV iron Injectafer and anticoagulant Xarelto could help bolster use of the drugs in particular segments of patients, though there were still lingering questions. Cardiologists we spoke with also had a great deal of enthusiasm for the SGLT-2 inhibitors in diabetic patients with CV disease due to Jardiance’s EMPA-REG results, which were highlighted in one session.
On the device front, HeartMate 3 encouragingly performed better than the previous-generation left ventricular assist device on short-term outcomes, though since this was only due to less pump malfunction, longer-term data from the study will be needed to see if there are any other advantages.
The bullets below provide highlights from these and other presentations.
Dyslipidemia
Heart Failure
Anticoagulation and Antiplatelet Therapy
CV Outcomes Trials (CVOTs) of Diabetes Drugs
This report also includes news or data on other drugs and topics, such as: data on the usage of PCSK9 inhibitors, neprilysin inhibitor TD-0714 (Theravance), anticoagulants betrixaban (PTLA) and VE 1902 (Verseon), and PAD cell therapy MarrowStim (ZBH).
Summary ……………………………………………………………………………………………………………………………………. 2
Dyslipidemia ……………………………………………………………………………………………………………………………. 7
Inclisiran (MDCO, ALNY) ………………………………………………………………………………………………………… 7
Repatha (evolocumab; AMGN, Astellas) …………………………………………………………………………………. 10
MDCO-216 (MDCO, PFE) and CSL112 (CSL Limited) …………………………………………………………………. 13
Evinacumab (REGN) and IONIS ANGPTL3-LRx (IONS) ……………………………………………………………….. 16
Other dyslipidemia notes …………………………………………………………………………………………………….. 19
Heart Failure ………………………………………………………………………………………………………………………….. 19
Injectafer (iron ferric carboxymaltose; Daiichi, Fresenius, Galenica, Zenia) …………………………………. 19
Ularitide (Cardiorentis, PDLI, Pharis) ……………………………………………………………………………………… 22
HeartMate 3 (STJ) ……………………………………………………………………………………………………………….. 25
Other heart failure notes ……………………………………………………………………………………………………… 27
Anticoagulation ……………………………………………………………………………………………………………………… 27
Xarelto (rivaroxaban; JNJ, BAYRY) ………………………………………………………………………………………….. 27
Other anticoagulation notes …………………………………………………………………………………………………. 31
Antiplatelet Therapy ……………………………………………………………………………………………………………….. 32
Brilinta (ticagrelor; AZN, MDCO)……………………………………………………………………………………………. 32
Cardiovascular Outcomes Trials of Type 2 Diabetes Drugs …………………………………………………………… 33
SGLT-2 inhibitors ………………………………………………………………………………………………………………… 34
GLP-1 agonists ……………………………………………………………………………………………………………………. 34
DPP-IV inhibitors …………………………………………………………………………………………………………………. 35
Primary care view ……………………………………………………………………………………………………………….. 35
Cell Therapy …………………………………………………………………………………………………………………………… 36
MarrowStim (ZBH) ………………………………………………………………………………………………………………. 36
List of 2016 Biomedtracker and Meddevicetracker AHA Events ……………………………………………………….. 38
Figure: LDL-C reductions of One Dose and Two Doses (300mg doses) versus Placebo up to 180 days
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!